FY25 consensus $935.7M. The company is updating its full-year outlook. Primarily due to the strengthening of the U.S. dollar and, to a lesser degree, a delay in the ramp-up of sample collection production and the voluntary attrition of genomics revenue related to restructuring activities, revenue is now expected to be in the range of $905M-$925M. Adjusted EBITDA is now expected to be in the range of $205M-$215M, down from prior view of $215M-$235M, primarily reflecting the impact of lower revenue and higher shipping and distribution costs. The company continues to expect capital expenditures to be approximately $85M, including approximately $55M related specifically to the integration of the former 3M Food Safety Division.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEOG:
- Neogen Announces Leadership Transition and New Appointments
- Options Volatility and Implied Earnings Moves This Week, January 06 – January 10, 2025
- Micron downgraded, Block upgraded: Wall Street’s top analyst calls
- Guggenheim sees Neogen ‘turning the corner,’ starts with a Buy
- Neogen initiated with a Buy at Guggenheim